Insights
Insights From Our Experts
Articles
Innovative Payer Strategies Demand Innovative NAM Strategies
EVERSANA’s Rich Heddens, Senior Vice President, Payer Strategy & Execution, and Dino Tsamparlis, Vice President, Market Access, discuss how innovative payer strategies call for innovative National Account Manager (NAM) strategies. The industry is facing unique challenges…
Plasma derived medicinal products – What is the way forward?
Content for this article was contributed by the EVERSANA Asia Pacific team. Plasma-derived products have a long history of providing benefits, especially in fractions addressing coagulation. Plasma is a rich biological substance and one of the…
EVERSANA’s Value & Evidence Team’s Work Tops List of Most Read Articles in 2021 in Journal of Comparative Effectiveness Research
If you work in the field of Health Economics and Outcome Research (HEOR) in the life sciences industry, you know just how valuable the Journal of Comparative Effectiveness Research (JCER) is. The publication features peer-reviewed studies…
Social Determinants of Health – What Pharma Can Do!
The US Department of Health and Human Services defines Social Determinants of Health (SDoH) as conditions in the places where people live, learn, work, and play that affect a wide range of health risks and outcomes.1…
Three Keys to Value for Unlocking the Promise of Cell Therapies
The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1 The revenue generation is being driven…
In the Emerging World of Prescription Digital Therapeutics (PDTs), Can You Really be Prescriptive?
Posted by
Anindita Banerjee on July 13, 20227/13/22
Breaking Down the 5Cs of Clinical and Commercial Success The past 2+ years of my 12-year career as a client strategy and services lead has thrown me into the ever-evolving world of prescription digital therapeutics (PDTs).…
Established Pharma Brands – A Good Investment?
Offering high cash flows with low clinical and commercial risks, established brands are gaining attention. Big pharma, such as Merck, GlaxoSmithKline (GSK), Pfizer and Sanofi, are spinning off their established brand drugs into new companies. Merck…